PLUS THERAPEUTICS, INC. financial data

Symbol
PSTV on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 30 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 91% % 65%
Debt-to-equity -295% % -3.3%
Return On Equity 336% % 24%
Return On Assets -173% % -18%
Operating Margin -256% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 137,429,055 shares 2231%
Common Stock, Shares, Outstanding 131,605,544 shares 2132%
Entity Public Float $8,200,000 USD 41%
Common Stock, Value, Issued $132,000 USD 2100%
Weighted Average Number of Shares Outstanding, Basic 107,428,969 shares 1268%
Weighted Average Number of Shares Outstanding, Diluted 107,428,969 shares 1268%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $5,258,000 USD -4.1%
Research and Development Expense $7,624,000 USD -32%
General and Administrative Expense $11,090,000 USD 21%
Operating Income (Loss) $13,456,000 USD 8.2%
Nonoperating Income (Expense) $7,120,000 USD -503%
Net Income (Loss) Attributable to Parent $20,576,000 USD -60%
Earnings Per Share, Basic -1 USD/shares 26%
Earnings Per Share, Diluted -1 USD/shares 27%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,289,000 USD 987%
Other Assets, Current $985,000 USD 71%
Assets, Current $17,586,000 USD 228%
Property, Plant and Equipment, Net $273,000 USD -54%
Operating Lease, Right-of-Use Asset $20,000 USD -81%
Goodwill $372,000 USD 0%
Other Assets, Noncurrent $45,000 USD 41%
Assets $18,670,000 USD 168%
Accounts Payable, Current $9,474,000 USD 99%
Liabilities, Current $13,616,000 USD 12%
Operating Lease, Liability, Noncurrent $31,000 USD -64%
Liabilities $13,616,000 USD 12%
Retained Earnings (Accumulated Deficit) $510,152,000 USD -4.2%
Stockholders' Equity Attributable to Parent $5,054,000 USD
Liabilities and Equity $18,670,000 USD 168%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,172,000 USD -37%
Net Cash Provided by (Used in) Financing Activities $12,405,000 USD
Net Cash Provided by (Used in) Investing Activities $3,558,000 USD
Common Stock, Shares Authorized 2,000,000,000 shares 1900%
Common Stock, Shares, Issued 131,863,969 shares 2042%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,791,000 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $23,000 USD -68%
Deferred Tax Assets, Valuation Allowance $22,575,000 USD 16%
Deferred Tax Assets, Gross $22,590,000 USD 16%
Operating Lease, Liability $75,000 USD -63%
Payments to Acquire Property, Plant, and Equipment $3,000 USD -92%
Lessee, Operating Lease, Liability, to be Paid $80,000 USD -63%
Property, Plant and Equipment, Gross $3,588,000 USD 4.2%
Operating Lease, Liability, Current $21,000 USD -69%
Lessee, Operating Lease, Liability, to be Paid, Year Two $11,000 USD -82%
Lessee, Operating Lease, Liability, to be Paid, Year One $69,000 USD -53%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 9.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,000 USD -58%
Deferred Tax Assets, Operating Loss Carryforwards $15,412,000 USD 15%
Preferred Stock, Shares Issued 1,952 shares 0%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $424,000 USD 3.9%
Additional Paid in Capital $515,574,000 USD 6.3%
Preferred Stock, Shares Outstanding 1,952 shares 0%
Depreciation, Depletion and Amortization $146,000 USD -5.8%
Deferred Tax Assets, Net of Valuation Allowance $15,000 USD -65%
Interest Expense $210,000 USD -64%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%